FRI0584 Rheumatic and musculoskeletal disorders related to immune checkpoint inhibitors in cancer patients: a prospective single-institution study
Khaled marie(Hôpital Pellegrin), Thierry Schaeverbeke(Inserm), Marine Gross‐Goupil(Centre Hospitalier Universitaire de Bordeaux), Florent Martin(Centre Hospitalier Universitaire de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Christophe Richez(Boston University), B Bannwarth(Centre Hospitalier Universitaire de Bordeaux), Rémi Veillon(Centre Hospitalier Universitaire de Bordeaux), Anne Pham‐Ledard(Peter MacCallum Cancer Centre), Nadia Mehsen-Cêtre(Bordeaux Population Health), M. Beylot‐Barry, L. Rouxel(Centre Hospitalier Universitaire de Bordeaux), S. Prey(Centre Hospitalier Universitaire de Bordeaux)
Cited by 1
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k